Ignite Creation Date:
2025-12-24 @ 11:50 PM
Ignite Modification Date:
2026-01-03 @ 3:12 PM
Study NCT ID:
NCT05225051
Status:
UNKNOWN
Last Update Posted:
2022-03-09
First Post:
2022-01-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
N- Homocysteinylated Huntingtin in Huntington's Disease
Sponsor:
Central Hospital, Nancy, France
Organization:
Study Overview
Official Title:
N-homocysteinylated Huntingtin in Huntington's Disease
Status:
UNKNOWN
Status Verified Date:
2022-03
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
HO-HD
Brief Summary:
Descriptive analysis of N- homocysteinylated Huntingtin in 3 groups of human fibroblasts:
1. presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin),
2. symptomatic HD individuals with motor UHDRS \> 5 (Mutated Huntingtin)
3. human control cell lines, unmutated Huntingtin
1. presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin),
2. symptomatic HD individuals with motor UHDRS \> 5 (Mutated Huntingtin)
3. human control cell lines, unmutated Huntingtin
Detailed Description:
Prospective inclusions of 32 subjects with 24 symptomatic HD patients and 8 presymptomatic HD patients.Rationale: This is a pilot study in humans. Over a period of 2 years, the potential recruitment should make it possible to include 32 patients This number will make it possible to calculate the overall variability of the dosage and to have statistics of position and dispersion in the 2 subgroups identified.
Controls: Eight standardized cell lines from human fibroblasts
Controls: Eight standardized cell lines from human fibroblasts
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: